DOP2011000044A - Metodos para tratar la talasemia - Google Patents
Metodos para tratar la talasemiaInfo
- Publication number
- DOP2011000044A DOP2011000044A DO2011000044A DO2011000044A DOP2011000044A DO P2011000044 A DOP2011000044 A DO P2011000044A DO 2011000044 A DO2011000044 A DO 2011000044A DO 2011000044 A DO2011000044 A DO 2011000044A DO P2011000044 A DOP2011000044 A DO P2011000044A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- treat
- talasemia
- methods
- thalassemia
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En Ia presente invención se proporciona un método para tratar, mejorar, o retrasar aI menos un síntoma de un trastorno sanguíneo genético, por ejemplo, anemia drepanocítica o talasemia, en un paciente que lo necesite, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2. También se proporciona en parte un método para reducir un bazo dilatado en un paciente que padece talasemia, que comprende administrar una cantidad terapéuticamente eficaz de un inhibidor de Jak2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8623308P | 2008-08-05 | 2008-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2011000044A true DOP2011000044A (es) | 2011-04-30 |
Family
ID=41581108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2011000044A DOP2011000044A (es) | 2008-08-05 | 2011-02-03 | Metodos para tratar la talasemia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110269721A1 (es) |
| EP (1) | EP2355827A2 (es) |
| JP (1) | JP2011530517A (es) |
| KR (1) | KR20110053347A (es) |
| CN (1) | CN102112131A (es) |
| AU (1) | AU2009279825A1 (es) |
| BR (1) | BRPI0917575A2 (es) |
| CA (1) | CA2732791A1 (es) |
| CL (1) | CL2011000242A1 (es) |
| CO (1) | CO6351728A2 (es) |
| CR (1) | CR20110115A (es) |
| DO (1) | DOP2011000044A (es) |
| EC (1) | ECSP11010847A (es) |
| IL (1) | IL211061A0 (es) |
| MA (1) | MA32611B1 (es) |
| MX (1) | MX2011001426A (es) |
| NI (1) | NI201100031A (es) |
| RU (1) | RU2011108563A (es) |
| SV (1) | SV2011003823A (es) |
| WO (1) | WO2010017122A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456176B2 (en) | 2004-04-08 | 2008-11-25 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| MX2007002208A (es) | 2004-08-25 | 2007-05-08 | Targegen Inc | Compuestos hetrociclicos y metodos de uso. |
| US7528143B2 (en) | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8486941B2 (en) | 2007-03-12 | 2013-07-16 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine compounds and uses thereof |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| CN103370068A (zh) * | 2010-12-03 | 2013-10-23 | Ym生物科学澳大利亚私人有限公司 | Jak-2 介导的病症的治疗 |
| WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| CN103664799A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| TR201911151T4 (tr) | 2013-03-14 | 2019-08-21 | Tolero Pharmaceuticals Inc | Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri. |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
| BR112018071093A2 (pt) * | 2016-04-15 | 2019-01-29 | Epizyme Inc | composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo |
| US20200113901A1 (en) * | 2017-03-31 | 2020-04-16 | Epizyme, Inc. | Methods of using ehmt2 inhibitors |
| AU2018254577B2 (en) | 2017-04-21 | 2024-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| EA202090955A1 (ru) * | 2017-10-18 | 2020-11-27 | Эпизайм, Инк. | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови |
| CN112533602A (zh) | 2018-04-05 | 2021-03-19 | 大日本住友制药肿瘤公司 | Axl激酶抑制剂及其用途 |
| MX2020010556A (es) | 2018-04-13 | 2021-03-02 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. |
| CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
| US20210355088A1 (en) * | 2018-09-07 | 2021-11-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
| MX2021009371A (es) | 2019-02-12 | 2021-09-10 | Sumitomo Pharma Oncology Inc | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos. |
| CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| CN112778282B (zh) * | 2021-01-06 | 2022-07-22 | 温州医科大学 | 一种嘧啶类小分子化合物及其应用 |
| WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7528143B2 (en) * | 2005-11-01 | 2009-05-05 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
-
2009
- 2009-08-03 MX MX2011001426A patent/MX2011001426A/es not_active Application Discontinuation
- 2009-08-03 RU RU2011108563/15A patent/RU2011108563A/ru not_active Application Discontinuation
- 2009-08-03 CA CA2732791A patent/CA2732791A1/en not_active Abandoned
- 2009-08-03 KR KR1020117005224A patent/KR20110053347A/ko not_active Application Discontinuation
- 2009-08-03 US US13/057,133 patent/US20110269721A1/en not_active Abandoned
- 2009-08-03 AU AU2009279825A patent/AU2009279825A1/en not_active Abandoned
- 2009-08-03 JP JP2011522136A patent/JP2011530517A/ja active Pending
- 2009-08-03 WO PCT/US2009/052544 patent/WO2010017122A2/en active Application Filing
- 2009-08-03 BR BRPI0917575A patent/BRPI0917575A2/pt not_active IP Right Cessation
- 2009-08-03 CN CN2009801303954A patent/CN102112131A/zh active Pending
- 2009-08-03 EP EP09741504A patent/EP2355827A2/en not_active Withdrawn
-
2011
- 2011-02-01 SV SV2011003823A patent/SV2011003823A/es not_active Application Discontinuation
- 2011-02-02 NI NI201100031A patent/NI201100031A/es unknown
- 2011-02-03 IL IL211061A patent/IL211061A0/en unknown
- 2011-02-03 DO DO2011000044A patent/DOP2011000044A/es unknown
- 2011-02-04 CL CL2011000242A patent/CL2011000242A1/es unknown
- 2011-02-28 EC EC2011010847A patent/ECSP11010847A/es unknown
- 2011-03-02 CR CR20110115A patent/CR20110115A/es not_active Application Discontinuation
- 2011-03-04 CO CO11026653A patent/CO6351728A2/es not_active Application Discontinuation
- 2011-03-04 MA MA33672A patent/MA32611B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0917575A2 (pt) | 2019-09-24 |
| SV2011003823A (es) | 2011-08-15 |
| IL211061A0 (en) | 2011-04-28 |
| WO2010017122A2 (en) | 2010-02-11 |
| US20110269721A1 (en) | 2011-11-03 |
| CA2732791A1 (en) | 2010-02-11 |
| CL2011000242A1 (es) | 2011-04-08 |
| ECSP11010847A (es) | 2011-07-29 |
| CN102112131A (zh) | 2011-06-29 |
| CO6351728A2 (es) | 2011-12-20 |
| EP2355827A2 (en) | 2011-08-17 |
| MA32611B1 (fr) | 2011-09-01 |
| KR20110053347A (ko) | 2011-05-20 |
| CR20110115A (es) | 2011-06-03 |
| RU2011108563A (ru) | 2012-09-10 |
| NI201100031A (es) | 2011-09-26 |
| WO2010017122A3 (en) | 2010-04-08 |
| MX2011001426A (es) | 2011-03-21 |
| JP2011530517A (ja) | 2011-12-22 |
| AU2009279825A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2011000044A (es) | Metodos para tratar la talasemia | |
| CO2020006009A2 (es) | Métodos de uso de inhibidores de ehmt2 para tratar o prevenir trastornos sanguíneos | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| CO6390109A2 (es) | Inhibidores de syk de imidazopirazina | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
| WO2006093348A3 (en) | Method and composition for treating peripheral vascular diseases | |
| EA201290041A1 (ru) | Лечение расстройств, связанных с макрофагами | |
| EP2581092A4 (en) | AGENT IMPROVING THE METABOLISM OF LIPIDS | |
| MX2012010418A (es) | Inhibidores syk de imidazopiridinas. | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX2009005649A (es) | Tratamiento para mieloma multiple. | |
| WO2007098099A3 (en) | Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor | |
| BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
| BR112012033738A2 (pt) | método para o tratamento de transtorno bipolar | |
| BR112015000808A2 (pt) | regime de dosagem para inibidores de janus quinase (jak) | |
| WO2009124294A3 (en) | Pharmaceutical compositions for binding sphingosine-1-phosphate | |
| TW200740441A (en) | Methods and reagents for the treatment of inflammatory disorders | |
| WO2008031835A3 (en) | Method of treating autoimmune diseases using vegf-pathway inhibitors | |
| WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
| BR112014000889A2 (pt) | tratamento para hipoxia | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| EA201100187A1 (ru) | Селективные ингибиторы ммр-12 и ммр-13 на основе гидроксамовой кислоты |